Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| D012127 | Respiratory Distress Syndrome, Newborn NIH | 0.08 |
| D055371 | Acute Lung Injury NIH | 0.08 |
| D012128 | Respiratory Distress Syndrome, Adult NIH | 0.07 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
This is a pilot phase, open label, non-randomized study for the treatment of ARDS in patients infected with COVID-19. Subjects will be enrolled and treated with one dose of mesenchymal stem cells and follow-up will occur 90 days post-treatment.
Description: Number of patients with changes in percentage of resting Oxygen saturation (%O2)
Measure: Oxygen saturation Time: Baseline, and at days 2, 4 and 14 post-treatmentDescription: Changes in mmHg of Arterial partial pressure of oxygen / Fraction of inspiration O2 (PaO2/FiO2) in all participants
Measure: Oxygen pressure in inspiration Time: Baseline, and at days 2, 4 and 14 post-treatmentDescription: Changes in percentage of participants with reduction in bilateral ground-glass opacities
Measure: ground-glass opacity Time: Baseline, and at day 14 post-treatmentDescription: Changes in percentage of participants with reduction of pneumonia bilateral infiltration
Measure: Pneumonia infiltration Time: Baseline, and at day 14 post-treatmentDescription: Number of participants with a reduction in Lactate dehydrogenase (mg/dL)
Measure: Lactate dehydrogenase Time: Baseline, and at days 4 and 14 post-treatmentDescription: Number of participants with a reduction in C-reactive protein (mg/dL)
Measure: C-reactive protein Time: Baseline, and at days 4 and 14 post-treatmentDescription: Number of participants with a reduction in D-dimer (mg/dL)
Measure: D-dimer Time: Baseline, and at days 4 and 14 post-treatmentDescription: Number of participants with a reduction in Ferritine (mg/dL)
Measure: Ferritine Time: Baseline, and at days 4 and 14 post-treatmentAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports